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Mutations targeting the 
coagulation pathway are enriched 
in brain metastases
Cristina Richichi1, Lorenzo Fornasari1, Giorgio E. M. Melloni2, Paola Brescia1, Monica Patanè3, 
Massimiliano Del Bene4, Dana A. M. Mustafa5, Johan M. Kros5, Bianca Pollo3, Giancarlo 
Pruneri6,7, Angela Sciandivasci8, Elisabetta Munzone  8, Francesco DiMeco4,9, Pier Giuseppe 
Pelicci1,10, Laura Riva2 & Giuliana Pelicci1,11
Brain metastases (BMs) are the most common malignancy of the central nervous system. Recently 
it has been demonstrated that plasminogen activator inhibitor serpins promote brain metastatic 
colonization, suggesting that mutations in serpins or other members of the coagulation cascade can 
provide critical advantages during BM formation. We performed whole-exome sequencing on matched 
samples of breast cancer and BMs and found mutations in the coagulation pathway genes in 5 out of 
10 BM samples. We then investigated the mutational status of 33 genes belonging to the coagulation 
cascade in a panel of 29 BMs and we identified 56 Single Nucleotide Variants (SNVs). The frequency of 
gene mutations of the pathway was significantly higher in BMs than in primary tumours, and SERPINI1 
was the most frequently mutated gene in BMs. These findings provide direction in the development of 
new strategies for the treatment of BMs.
Brain metastases (BMs) are the most common malignancy of the central nervous system, and their incidence is 
dramatically increasing due to the improvements in overall survival of primary tumour patients and failure of sys-
temic chemotherapy to reach the central nervous system1. Mainly, BMs derive from primary tumours originating 
in the breast, lung, skin, gastrointestinal tract and kidney2, 3.
Breast cancer (BC) is a heterogeneous disease that remains the second leading cause of death among women 
worldwide4: up to 16% of patients with metastatic BC develop symptomatic BMs during the course of their dis-
ease, and another 10% of patients have asymptomatic brain involvement in post-mortem autopsies5, 6. Because 
of improvements in the treatment of patients with metastatic breast cancer, the development of brain metas-
tases has become a major impediment to improved life expectancy and quality of life for many breast cancer 
patients. The median survival time is very short, ranging from 2 to 25 months despite treatment7–10. In addition, 
the intra-tumour and inter-tumour heterogeneity of BC influences the clinical course of the disease and the 
response to treatment.
Although some gene expression signatures have been previously associated with metastasis to the brain11, 12, 
the driver mutations that lead to the formation of BM are still largely unknown. Although the frequency of 
these mutations is fairly low, the metastatic spread is sustained by gene mutations conferring selective growth 
advantage to target cells13–15. Large-scale genome sequencing of human tumours found little evidence for specific 
metastasis-associated mutations other than mutations in classic initiator oncogenes (driver genes) that are also 
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present in primary tumours and enriched in metastatic lesions16. We therefore searched for metastasis-associated 
mutations in genes that belong to the same pathway but do not fall in recognized oncogenes.
Results and Discussion
All the surgical specimens employed in this study were collected from consenting patients at Istituto Neurologico 
“Carlo Besta”, Milan, Italy, European Institute of Oncology, Milan, Italy and Erasmus University Medical Center, 
Rotterdam, The Netherlands.
We performed whole-exome sequencing (WES) (Illumina Hiseq. 2000 platform with 101 bp paired-end reads) 
of primary breast tumour and BMs from 10 patients (Supplementary Table S1a). For 7 patients we could perform 
WES of the matched normal brain tissue while for 3 patients (S_2, S_4 and S_9) the normal sample was unavaila-
ble. To identify metastasis-specific mutations, we compared each metastasis sample to the corresponding tumour 
DNA and to the normal DNA, when available. We identified somatic mutations, including single nucleotide 
variants (SNVs, using MuTect17) and small insertions and deletions (indels, using Indelocator), present in each 
primary BC and in the corresponding metastasis. Since we analysed somatic mutations in multiple samples for 
the same patient, to increase sensitivity in mutation-calling we merged the mutations identified in each sample 
(i.e. SNVs and indels called in the metastasis sample and tumour sample compared to the matched normal sam-
ple), and we counted the number of alternative and reference reads supporting the mutations in all the samples. 
Duplicated reads were not considered in this calculation. In addition, we selected variants that were present only 
in the metastasis, or with a variant allele frequency (VAF) significantly higher in the metastasis compared to the 
matched primary tumour (Fisher’s exact test corrected for FDR, values in Supplementary Table S2). The availabil-
ity of normal samples allowed us to assess which somatic mutations were present in both primary and metastasis 
samples at higher frequency in the metastasis compared to the primary sample. Considering non-synonymous 
SNVs occurring with an allelic frequency of at least 5% (corresponding to a fraction of mutated cells of 10% or 
more, assuming the majority of mutations to be heterozygous), we identified 68 indels and 831 metastasis-specific 
SNVs. Of the 686 mutated genes, 78 were found in at least 2 patients, and among these 25 in at least 3 patients 
(Supplementary Table S2). Eight genes (CD46, F5, C1QB, C5, FGA, SERPINA1, VWF, SERPINA10) (seven with a 
unique mutation) found mutated in seven patients belong to the complement and coagulation cascade pathway 
(see Supplementary Figure S1). We found this pathway to be ranked as the third highlighted pathway and the 
first “not cancer” pathway as a result of analysis with Enrichr, an enrichment analysis web-based tool ((http://
amp.pharm.mssm.edu/Enrichr/; Supplementary Table S4).
Recent studies have shown that plasmin from the reactive brain stroma, which is lethal to cancer cells passing 
through the blood-brain-barrier, acts as a natural defence against metastatic invasion, and plasminogen activator 
(PA)-inhibitor serpins in cancer cells sustain the mechanism for the metastatic colonization of the brain18. These 
findings suggest that mutations in serpins and possibly other members of the coagulation cascade are critical to 
the formation of BMs. Interestingly, loss of function of one of these genes, FGA, is described as driving metastasis 
in vivo19.
To validate the metastasis-specific mutations identified through the whole-exome sequencing analysis, we 
investigated the mutational status of 33 genes belonging to the complement and coagulation cascade pathway in 
an independent panel of BMs using the MiSeq sequencing system. We included in our panel the serpin-family 
genes (SFGs) since they have been previously described as relevant for the metastatization process18 and all the 
other genes belonging to the coagulation pathway that crosstalk with SFGs (see Supplementary Figure S1). Few 
genes (F8, F9 and F13) were excluded because the sequences were highly repetitive causing errors in the sequenc-
ing output, while few others (F2R, PLAUR, A2M, PROS1) were left out because these are genes involved in other 
signalling pathways. For the complement cascade, we included in the examination only upstream gene regulators, 
besides those genes found mutated with WES. We analysed 29 BMs derived from lung (n = 10), kidney (n = 7) 
and breast cancer (n = 12) (Fig. 1; Supplementary Table S1b). Six of the BC samples belong to samples previously 
analysed with WES (i.e. S_3, S_6, S_7, S_8, S_11, S_10). Mutations in the F5 gene found in two patients were not 
validated with the Illumina MiSeq sequencing system described here. We identified 56 SNVs in 17 out of 29 BM 
samples distributed in 70% of patients with primary lung tumour, 58% of patients with breast primary tumour 
and 43% of patients with kidney primary tumour (Fig. 1a; Supplementary Table S3).
We analysed public gene mutation profiles of primary tumours coming from the cBioPortal20, 21 from distinct 
organs, and we found that the frequency of samples with at least one of the complement and coagulation path-
way genes mutated was significantly lower than in BMs (12% in breast cBioPortal samples against 58% in our 
breast samples, 12% in kidney against 43% and 40% in lung cancer against 70%; Table 1 and in Supplementary 
Table S5). There is recent data showing that clinically actionable alterations in BMs are often not present in pri-
mary tumours. Such mutations may represent de novo alterations in BMs characteristic of the ancestral precursor 
of the metastatic process16. Among the 33 genes analysed in BMs, 27 genes were found mutated at least once 
(Fig. 1b–d; Supplementary Figure S1). The distribution of the mutated serpins among the samples shows a mutu-
ally exclusive pattern in breast (Fig. 1b) and in kidney (Fig. 1d). Among the 8 samples with a single mutated gene 
in the coagulation and complement cascade pathways, 6 had a mutation on a serpin gene, suggesting a possible 
self-sustainability of serpins for the entire pathway. Among SFGs, SERPINI1 is the most frequently mutated gene, 
and the conserved residue S88 mutated to phenylalanine in two of our patients is the same residue mutated to 
alanine through a mutagenesis assay that results in an alteration of the SERPINI1-tPA inhibitory complex22.
Despite the existence of several targeted therapies toward pivotal pathways in BC, the effect of drugs acting 
on the coagulation pathway in BM establishment and development is still unexplored. Our results suggest that 
the alteration of this pathway, even with a mutation of a single gene, could be a key step in the establishment of 
BMs. In fact, hypercoagulable state (and disorganized angiogenesis) is closely linked to tumour progression and 
metastatic potential, and a considerable number of clinical trials are focused on the effects of anticoagulant (and 
antiangiogenic) drugs on survival in cancer patients23.
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After invading the bloodstream, tumour cells need to overcome the stress associated with circulatory pas-
sage, circulation patterns and extravasation barriers to invade, seed and form metastases24. The present findings 
support further investigations aiming at the candidacy of serpins and other molecules that take part in blood 
coagulation for future anti-metastatic treatment. We specifically looked at “druggable” mutated serpins since the 
efficacy of drug-like anti-cancer compounds in modulating serpin family members has already been shown25, 26. 
In particular, molecules targeting proteins of the serpin family may be applied to the management of patients with 
brain metastases.
Figure 1. Distribution of somatic specific mutations. (a) Summary table of our 29 samples, including number 
of subjects per tumour type, total number of mutations found in coagulation and complement pathways, and 
number of unique genes mutated. (b–d) Oncoprint plots showing 33 genes belonging to the coagulation (26 
genes, in green) and complement (7 genes, in orange) pathways on the rows and samples from three different 
primary tumours on the columns, (b) breast, (c) lung and (d) kidney respectively (17 out of 29 patients have at 
least one mutation on these pathways). Numbers in parenthesis represents the number of samples mutated on 
the specific gene (rows) and the number of mutated genes per sample (columns). Scales of blue indicates if a 
sample harbors one or more mutations on the same gene.
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Methods
Identification of metastatic-specific mutations by whole-exome sequencing. The whole proce-
dure was carried out using experimental protocols approved by the institutional review board of the European 
Institute of Oncology, Milan, Italy. We confirmed that all methods were performed in accordance with the rel-
evant guidelines and regulations and that informed consents were collected from patients in the Department 
of Neurosurgery at IRCCS Foundation Neurological Institute “Carlo Besta”, Milan, Italy, and from the Erasmus 
University Medical Center, Rotterdam, The Netherlands, under the corresponding research ethics committee 
approval.
We performed whole-exome sequencing (WES) on the Illumina HiSeq. 2000 platform with 101 bp paired-end 
reads of primary breast tumour and BMs from 10 patients. DNA of patients’ samples was extracted from 
paraffin-embedded (FFPE) tissues and prepared using the Qiagen DNeasy Blood & Tissue Kit, fragmented and 
used for Illumina Truseq library construction. To extract DNA, normal and tumoural tissue 3-4 0.6 mm core 
punch biopsies were prepared. Cores were chosen primarily based on sample morphology, observing hematox-
ylin and eosin staining: patients’ specimens were fixed in Carnoy’s solution, dehydrated, paraffin-embedded and 
sectioned at 2 μm according to established procedures. Slides were then stained in Carazzi hematoxylin solution, 
rinsed in running tap water and counterstained in eosin solution. Metastatic tissue was sharply defined and the 
adjacent nervous tissue contained unequivocal normal tissue (see Supplementary Figure S2)27. Patient normal 
DNA from blood was unavailable due to patients’ deaths.
Exome-capture was carried out for all the samples using the SureSelectXT Human All Exon Kit, accord-
ing to the manufacturer’s instructions (Agilent Technologies, Santa Clara, CA). Alignment to the reference 
genomes (hg19) was performed using Burrows Wheeler Aligner (BWA)19. We performed the following NGS data 
pre-processing steps, according to GATK best practices20: local realignment, duplicate marking and base quality 
recalibration. SNVs were identified using MuTect10 and indels were identified using Indelocator (also part of 
GATK distribution), respectively. The identified variants were functionally annotated using ANNOVAR28, which 
annotates the mutations using publicly available databases (e.g. dbSNP29 and 1000 Genomes30) and identifies 
non-synonymous mutations. The frequency of each mutation was calculated by dividing the number of reads 
supporting the variant to the total coverage at the variant site.
To the identified SNVs and indels, we applied additional filters to ensure more reliable calls: i) a minimum 
coverage of 10 reads for both normal and tumour samples; ii) a minimum read depth of 5 for the alternate variant 
allele in at least one of the matched samples; iii) a variant allele frequency of at least 5% over all the reads covering 
the position. We excluded from further analysis variants in non-coding regions, synonymous variants, variants 
present in highly repetitive regions or variants annotated to be present in ExAC31, ESP (http://evs.gs.washington.
edu/EVS) and 1000 Genomes of European origin with minor allele frequency (MAF) > 0.01.
TOTAL Brain Metastasis TCGA_Primary OR
Permutation Test 
P-value Total
Mutated 17 578
5,796691 3,70E-06
Number of samples 2945
Not_Mutated 12 2367 Mutated Samples 578
Frequency 0,586206897 0,196264856 Frequency 0,196265
BREAST Brain Metastasis TCGA_Primary OR Permutation Test P-value brca Total
Mutated 7 155
9,932555 1,82E-04
Number of samples 1258 1258
Not_Mutated 5 1103 Mutated Samples 155 155
Frequency 0,583333333 0,123211447 Frequency 0,123211 0,1232114
LUNG Brain Metastasis TCGA_Primary OR Permutation Test P-value luad lusc sclc Total
Mutated 7 313
3,498197 5,34E-02
Number of samples 447 178 158 783
Not_Mutated 3 470 Mutated Samples 165 79 69 313
Frequency 0,7 0,399744572 Frequency 0,369127 0,443820 0,436709 0,399745
KIDNEY Brain Metastasis TCGA_Primary OR Permutation Test P-value kich kirc kirp Total
Mutated 3 110
5,396801 4,25E-02
Number of samples 66 556 282 904
Not_Mutated 4 794 Mutated Samples 9 81 20 110
Frequency 0,428571429 0,121681416 Frequency 0,136364 0,145683 0,070922 0,121681
Table 1. Comparison of the frequency of mutations in the coagulation and complement pathway between 
primary tumours from TCGA-database and brain metastases of our cohort. We compare frequencies of 
mutations based on the origin of primary tumours (breast, lung and kidney). Mutational profile of these 
tumours, analysed according to the pathways, indicates that coagulation and complement cascade genes carry 
mutations at frequency significantly lower than brain metastases in each of the 3 different datasets (breast, lung 
and kidney cancer). OR: odds ratio brca: breast carcinoma; luad: lung adenocarcinoma; lusc: lung squamous cell 
carcinoma; sclc: small cell lung cancer; kich: kidney chromophobe; kirc: kidney renal clear cell carcinoma; kirp: 
kidney renal papillary cell.
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Identifications of variants in genes belonging to the coagulation and complement pathway 
by Illumina Miseq. The Illumina MiSeq sequencing system was used to identify the variants present in 
selected genes in additional patients. Clinical characteristics of this independent cohort of patients are reported 
in Supplementary Table S1b. We also included in this analysis 6 samples previously analysed with WES (S_3, S_6, 
S_7, S_8, S_11, S_10) whose clinical characteristics are reported in Supplementary Table S1a. We used the TruSeq 
Custom Amplicon kit (Illumina) and designed a panel using DesignStudio covering the following selected genes: 
BDKRB1, C1QB, C3, C5, CD46, CFH, F10, F11, F12, F2, F3, F5, F7, FGA, KLKB1, PLAT, PLAU, PLG, PROC, 
SERPINA1, SERPINA10, SERPINA5, SERPINB2, SERPINC1, SERPIND1, SERPINE1, SERPINE2, SERPINF2, 
SERPING1, SERPINI1, TFPI, THBD, VWF. We performed enrichment and sequencing of the targeted regions 
according to the manufacturer’s instructions. We aligned sequencing data to the reference genome hg19 with 
BWA32, and we analysed them with the same pipeline used for WES data. Briefly, we carried out alignment to the 
reference genomes (hg19) using BWA19. We performed local realignment and base quality recalibration using 
GATK20. We did not perform the removal of duplicate reads because in assays using amplicon-based capture 
reagents, all amplification products have the same start and stop positions making it impossible to distinguish dif-
ferent DNA fragments from PCR duplicate reads33. SNVs were identified using MuTect10, indels with Indelocator 
and ANNOVAR to annotate the identified variants. We applied the same additional filters we used for WES anal-
ysis to the identified SNVs and indels.
Testing the difference in mutation frequency between primary tumours and metastasis. We 
checked for a higher frequency of mutations between our BM samples and public available samples from primary 
tumours contained in the cBioPortal database13, 14 on 33 genes in the complement and coagulation pathway. 
The cBioPortal database comprises the entire The Cancer Genome Atlas (TCGA) and most of the International 
Cancer Genome Consortium (ICGC) data and other smaller studies for a total of 1258 breast cancer samples, 783 
lung cancers and 904 kidney cancers. To test for a difference in frequency, we ran a permutation test to evaluate 
whether the frequency in BMs was consistent with a frequency calculated on a million random samples from 
breast, lung and kidney cBioPortal primary tumours of the same size of our BMs cohorts for each tumour type. 
P-value was calculated as the fraction of random samples whose frequency was below that in our BMs. This test 
was preferred to a more conservative Fisher’s exact test given the disproportion between our total sample size 
(29 samples) and the cBioPortal data (up to 1258 samples for breast cancer). Full results including the number of 
mutated samples for each tumour type are available in Table 1.
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